Amgen ACC.23/WCC
Back to ACC.23/WCC Home

Addressing Gaps in Cardiovascular Health

Cardiovascular disease is one of the most significant public health issues in the world. Our commitment to cardiovascular disease remains steadfast, and supporting cross-sector collaborative programs and patient-advocacy initiatives is part of this commitment. A key focus of this work is moving from a reactive healthcare model toward a proactive and innovative public health approach aimed to predict and prevent the impact of serious diseases from occurring. Together, we are employing and testing not just one approach but a range of innovative initiatives to help improve patient outcomes and address population health.

Family Heart Foundation

Sponsored by Amgen, the Family Heart Foundation's PPPLLL (Patient, Provider, and Payer Lipid Lowering Landscape (PPPLLL)) analysis seeks to understand how real world treatment of ASCVD aligns with treatment guidelines and recommendations for cholesterol management. Featuring heat maps, qualitative insights, and discussions on disparities in care, the Family Heart Foundation investigates real world rates of cholesterol control, utilization rates of combination therapy, as well as the average lengths of time most patients remain at goal once it is achieved.

AMGA ASCVD Best Practices Learning Collaborative

Amgen has joined Novartis in support of the American Medical Group Association Foundation’s new atherosclerotic cardiovascular disease (ASCVD) Best Practices Learning Collaboration, a 15-month initiative focused on helping medical groups develop strategies to improve the management and treatment of patients with ASCVD.

View Press Release
Million hearts campagin overview handout

Alliance for Million Hearts Campaign Overview

Amgen is part of the CDC Foundation’s Alliance for Million Hearts, a public-private coalition to help fuel the Million Hearts initiative toward its goal of preventing at least one million heart attacks, strokes and cardiovascular events. Download this overview to learn more about campaigns led by the Foundation to change the way people think about and embrace cardiovascular disease prevention.

Download Handout
Million hearts live to the beat postcard

Alliance for Million Hearts: Live to the Beat Campaign

The Alliance for Million Hearts launched the “Live to the Beat” campaign to help address cardiovascular disease (CVD) in the U.S. The campaign aims to reduce CVD risk among Black adults ages 35–54 with a focus on moving more, eating better, quitting smoking and addressing key risk factors like hypertension, high cholesterol and high blood sugar. Download this postcard to learn more or share with patient audiences.

Download Postcard

African American Heart Study

In collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), Amgen recently launched its African American Heart Study, which will measure the correlation of Lipoprotein(a), or Lp(a), and the relationship with atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States. It is a unique study including community outreach in partnership with trusted organizations to help improve our understanding of the disproportionately higher incidence of Lp(a) and cardiovascular disease progression in African Americans and provide insights to address barriers in clinical trial access.

View Press Release

CardioHealth Alliance

Amgen joined the CardioHealth Alliance to expedite evidence-based solutions for prevention and care of cardiovascular, renal, and cardiometabolic diseases. The CardioHealth Alliance brings together a multidisciplinary group of experts to improve disease care pathways and expedite the implementation of evidence into practice.

View Press Release

Amgen & StoryCorps Health Equity Series

Amgen, in collaboration with StoryCorps, launched the Every Patient Counts, Every Story Matters: Health Equity Series, which is designed to illuminate the shared experiences of individuals either facing health disparities or working to change them in the areas of cardiovascular disease, asthma, psoriasis and cancer.

Listen on Spotify

TRANSFORM: ACS

Amgen has partnered with the American College of Cardiology (ACC) on TRANSFORM: ACS, a program that aims to initiate lipid-lowering treatment closer to hospital discharge for ACS patients.

View Press Release

Optum Life Sciences Lowering Cardiovascular Disease Risk for Patients with Hyperlipidemia Pilot Program

Amgen partnered with Optum Life Sciences to pilot a program designed to improve awareness of and adherence to the American College of Cardiology (ACC) and American Heart Association (AHA) hyperlipidemia clinical guidelines for patients with hyperlipidemia by highlighting opportunities to help providers prioritize provider/patient discussions for treatment and lipid management options.

View Post

TEACH-ASCVD

Amgen has partnered with the National Lipid Association (NLA) Health Quality and Research (HQR) committee to determine effective ways to implement a system-based intervention that will provide practical solutions for the care of very-high risk ASCVD patients (e.g. recent MI) and high-risk patients with hyperlipidemia (ex. HeFH, HoFH). Visit lipid.org/teachascvd for more information or to volunteer to participate.

View website